Neeraj Pandey's Auron Mein Kahan Dum Tha, featuring Tabu and Ajay Devgn, has faced a poor box office debut in India. Early estimates suggest that Auron Mein Kahan Dum Tha earned between Rs 1.30 ...
Ajay Devgn and Tabu-starrer 'Auron Mein Kahan Dum Tha' had a slow start at the box office. On Day 2, the film did witness a growth but it was not very significant. The Neeraj Pandey directorial ...
Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025Series B Financing Funds ...
Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers. Auron Therapeutics has ...
Auron Therapeutics近日宣布成功完成2700万美元的B轮融资，目标是加速其在癌症治疗领域的研究。这家创新生物技术公司专注于通过细胞可塑性和分化疗法来战胜癌症，特别是致力于通过激活体内自然细胞程序，促使肿瘤细胞转变为健康细胞。
Auron Therapeutics是一家专注于开发针对失调分化和细胞可塑性治疗的癌症疗法公司。该公司专注于分化疗法，其可重新激活内源性细胞程序以引发肿瘤细胞成熟，向正常细胞功能转化。近日，Auron Therapeutics完成2700万美元的B轮融资。本次B轮融资由DCVC Bio领投，并得到了Apollo Health Ventures、Arkin Bio ...
今日，生物制药公司Auron Therapeutics宣布成功完成2700万美元的B轮融资，同时也获得了美国FDA对其创新抗癌药物AUTX-703的IND申请许可。这款潜在的‘first-in-class’ KAT2A/B蛋白降解剂将用于治疗血液恶性肿瘤，特别是针对急性髓系白血病（AML）。
▎药明康德内容团队编辑Auron Therapeutics公司今日宣布，该公司完成2700万美元的B轮融资。同时，其潜在“first-in-class”的KAT2A/B蛋白降解剂AUTX-703的IND申请已经获得美国FDA的许可。该公司正在启动AUTX-703治疗血液恶性肿瘤的临床试验。本次B轮融资由DCVC Bio领投，并得到了Apollo Health Ventures、Arkin Bio ...
12d
This February, &pictures brings a gripping tale of emotions, choices, and second chances with the &pictures premiere of Auron ...
NEWTON, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory ...
Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers. From the Boston Business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback